The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs

The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs

Eosinophilic esophagitis (EoE) is a multifaceted disease characterized by a wide heterogeneity of clinical manifestations, endoscopic and histopathologic patterns, and responsiveness to therapy. From the perspective of an effective approach to the patient, the different inflammatory mechanisms invol...

Full description

Bibliographic Details
Main Authors:	Erminia Ridolo, Alessandro Barone, Martina Ottoni, Silvia Peveri, Marcello Montagni, Francesca Nicoletta
Format:	Article
Language:	English
Published:	MDPI AG 2024-01-01
Series:	International Journal of Molecular Sciences
Subjects:	biological drugs benralizumab cendakimab dupilumab eosinophilic esophagitis lirentelimab mepolizumab
Online Access:	https://www.mdpi.com/1422-0067/25/3/1702

Similar Items

Combining Biologics Targeting Eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in Allergic and Inflammatory Diseases
by: Mitchell M. Pitlick, MD, et al.
Published: (2022-11-01)

IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma
by: Hideyasu Shimizu, et al.
Published: (2021-10-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
by: Erminia Ridolo, et al.
Published: (2020-10-01)

Characterization of Severe Uncontrolled Asthma in Japan: Analysis of Baseline Data from the PROSPECT Study
by: Koya T, et al.
Published: (2023-06-01)

Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma
by: Florence Roufosse
Published: (2018-04-01)

Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
by: Drick N, et al.
Published: (2020-11-01)

Efficacy of tezepelumab against uncontrolled severe non‐type 2 asthma refractory to bronchial thermoplasty, benralizumab, dupilumab and mepolizumab
by: Yoshiro Kai, et al.
Published: (2024-03-01)

Evidence-Based Approach of Biologic Therapy in Bronchial Asthma
by: Adnan Liaqat, et al.
Published: (2023-06-01)

Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction
by: Ramphul M, et al.
Published: (2021-05-01)

Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction [Corrigendum]
by: Ramphul M, et al.
Published: (2021-07-01)

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials
by: Noor Alam, et al.
Published: (2023-09-01)

A case of recurrent chronic eosinophilic pneumonia after switching from benralizumab to dupilumab
by: Daiki Nakashima, et al.
Published: (2024-01-01)

Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia
by: Kawabata H, et al.
Published: (2021-11-01)

A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils
by: Hiroshi Ohnishi, et al.
Published: (2022-06-01)

When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report
by: M. Sabbe, et al.
Published: (2024-01-01)

Initiation, response assessment, and switch of antibody therapies in patients with severe asthma – A survey among German specialists
by: Hendrik Suhling, MD, et al.
Published: (2023-12-01)

Unanswered questions on the use of biologics in pediatric asthma
by: Antonio Nieto, MD, PhD, et al.
Published: (2023-11-01)

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study
by: Santi Nolasco, et al.
Published: (2023-06-01)

Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective
by: Marco Caminati, et al.
Published: (2023-02-01)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
by: Giulia Scioscia, et al.
Published: (2023-06-01)

Adverse events of anti-IL-5 drugs in patients with eosinophilic asthma: a meta-analysis of randomized controlled trials and real-world evidence-based assessments
by: Wen Li, et al.
Published: (2024-02-01)

Taking a Breather: Advances in Interleukin 5 Inhibition for Asthma Relief
by: Oliver William Massey, et al.
Published: (2022-09-01)

Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE)
by: Marco Contoli, et al.
Published: (2022-04-01)

Targeting IL-5 in COPD
by: Narendra DK, et al.
Published: (2019-05-01)

Efectividad de mepolizumab y benralizumab en una cohorte de pacientes con asma grave eosinofílico en vida real
by: María José Espinosa de los Monteros Garde, et al.
Published: (2021-04-01)

Interleukin-5 in the Pathophysiology of Severe Asthma
by: Corrado Pelaia, et al.
Published: (2019-12-01)

Current and Novel Therapies for Eosinophilic Gastrointestinal Diseases
by: Giovanni Marasco, et al.
Published: (2023-10-01)

Management of Severe Asthma in Eosinophilic Granulomatosis with Polyangiitis with Interleukin-5-Targeted Therapies: Current Status and Report of Two Cases
by: Ciro Romano, et al.
Published: (2022-11-01)

Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series
by: Pelletier G, et al.
Published: (2022-05-01)

The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma
by: Laura Bergantini, et al.
Published: (2023-10-01)

Benralizumab treatment in an elderly patient with eosinophilic esophagitis resulted in remission: a case report
by: Azusa Ishii, et al.
Published: (2024-01-01)

Successful Introduction of Benralizumab for Eosinophilic Ascites
by: Nabil Belfeki, et al.
Published: (2024-01-01)

Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
by: Agamemnon Bakakos, et al.
Published: (2021-04-01)

Biological Therapy of Severe Asthma and Nasal Polyps
by: Agamemnon Bakakos, et al.
Published: (2022-06-01)

Successful simultaneous targeting of IgE and IL-5 in a severe asthmatic patient selected for lung transplantation
by: Karl-Christian Bergmann, PhD, MD, et al.
Published: (2022-08-01)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
by: Arian Ghassemian, et al.
Published: (2021-01-01)

First Therapeutic Approval for Eosinophilic Esophagitis
by: Rami A. Al-Horani, et al.
Published: (2022-07-01)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
by: S. K. Zyryanov, et al.
Published: (2020-12-01)

Eosinophilic Esophagitis
by: Samuel Costa, et al.
Published: (2016-05-01)

Severe eosinophilic bronchial asthma: new therapeutic options
by: N. M. Nenasheva
Published: (2018-10-01)